More studies based on robust and modern methods such as GWAS or NGS techniques, and focused on both genomic and epigenomic associations, need to be carried out on genetically diverse populations to provide stronger evidence and apply TGF-β gene polymorphisms in clinical practice as asthma development risk biomarkers. The gene discussed is TGFB1; the disease is asthma.